Viking Therapeutics, Inc. (VKTX) annual income statement — 14-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 |
|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 208K | 431K | 0 | 0 | 0 | 0 | 0 | 260K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | -208K | -431K | 0 | 0 | 0 | 0 | 0 | -260K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | 100% | - | - | - | - | - | - | - | - |
| Operating Expenses | 502M | 393.34M | 150.92M | 100.83M | 70.36M | 55.68M | 42.66M | 32.43M | 26.16M | 19.07M | 13.85M | 12M | 23.47M | 101.08K | 439 |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 48.28M | 48.39M | 49.28M | 37.02M | 16.12M | 10.7M | 10.73M | 8.87M | 7.12M | 5.33M | 4.85M | 5.03M | 1.24M | 89.46K | 163 |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 453.71M | 344.95M | 101.64M | 63.81M | 54.23M | 44.98M | 31.93M | 23.56M | 19.04M | 13.74M | 9M | 6.97M | 22.22M | 11.61K | 275 |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -502M | -393.34M | -150.92M | -100.83M | -70.36M | -55.68M | -42.66M | -32.69M | -26.16M | -19.07M | -13.85M | -12M | -23.47M | -101.08K | -439 |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -160.63% | -49.68% | -43.31% | -26.35% | -30.52% | -30.52% | -24.95% | -37.18% | -37.72% | -15.43% | 48.88% | -23118.16% | -22947.04% | - |
| EBITDA | -501.68M | -392.91M | -150.57M | -100.53M | -70.06M | -55.39M | -42.38M | -32.43M | 0 | -189 | 0 | -22.42M | -21.26M | -121.7K | 0 |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -191.79% | -160.94% | -49.77% | -43.49% | -26.5% | -30.67% | -30.71% | - | 100% | - | 100% | -5.49% | -17365.78% | - | - |
| D&A (Non-Cash Add-back) | 320K | 431K | 346K | 292K | 291K | 296K | 277K | 260K | 26.16M | 19.07M | 13.85M | -10.43M | 2.21M | -20.62K | 439 |
| EBIT | -502M | -393.34M | -150.92M | -100.83M | -70.36M | -55.68M | -39.39M | -25.63M | -21.5M | -18.63M | -12.7M | -22.39M | -23.47M | -121.7K | -109.64K |
| Net Interest Income | 29.61M | 33.7M | 40.85M | 14.93M | 1.53M | 685K | 3.13M | 6.9M | 2.71M | -1.85M | -1.95M | -982.18K | 0 | 0 | 0 |
| Interest Income | 29.64M | 33.7M | 40.94M | 15.02M | 1.59M | 703K | 3.23M | 7.05M | 3.27M | 98.14K | 83.62K | 36.32K | 0 | 0 | 6 |
| Interest Expense | 32K | 56K | 94K | 88K | 59K | 18K | 106K | 146K | 562K | 1.95M | 2.03M | 1.02M | 628.68K | 24.55K | 0 |
| Other Income/Expense | 29.66M | 33.7M | 40.96M | 14.93M | 1.49M | 692K | 3.17M | 6.91M | 4.1M | -1.51M | -884.55K | -11.41M | 1.58M | -45.17K | -110.59K |
| Pretax Income | -472.33M | -359.64M | -109.96M | -85.89M | -68.87M | -54.99M | -39.49M | -25.78M | -22.06M | -20.58M | -14.73M | -23.4M | -21.88M | -146.25K | -444 |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -6 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 1.35% |
| Net Income | -472.33M | -359.64M | -109.96M | -85.89M | -68.87M | -54.99M | -39.49M | -25.78M | -22.06M | -20.58M | -14.73M | -23.4M | -21.88M | -146.25K | -444 |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -268.33% | -227.05% | -28.02% | -24.73% | -25.24% | -39.23% | -53.21% | -16.84% | -7.22% | -39.68% | 37.05% | -6.94% | -14863.85% | -32830.5% | - |
| Net Income (Continuing) | -472.33M | -359.64M | -109.96M | -85.89M | -68.87M | -54.99M | -39.49M | -25.78M | -22.06M | -20.58M | -14.73M | -23.4M | -21.88M | -146.25K | -111.03K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -4.09 | -3.19 | -1.01 | -0.91 | -0.88 | -0.70 | -0.50 | -0.36 | -0.38 | -0.79 | -0.90 | -3.68 | -5.08 | -0.03 | -0.30 |
| EPS Growth % | -260% | -215.84% | -10.99% | -3.41% | -25.71% | -40% | -38.89% | 5.26% | 51.9% | 12.22% | 75.54% | 27.56% | -14885.25% | 88.7% | - |
| EPS (Basic) | - | -3.19 | -1.01 | -0.91 | -0.88 | -0.70 | -0.50 | -0.36 | -0.38 | -0.79 | -0.90 | -3.68 | -5.08 | -0.03 | -0.30 |
| Diluted Shares Outstanding | 115.57M | 112.67M | 109.04M | 94.35M | 76.83M | 77.2M | 72.6M | 71.96M | 57.58M | 25.98M | 16.28M | 6.36M | 4.31M | 4.31M | 1.48K |
| Basic Shares Outstanding | 115.57M | 112.67M | 109.04M | 94.35M | 76.83M | 77.2M | 72.6M | 71.96M | 57.58M | 25.98M | 16.28M | 6.36M | 4.31M | 4.31M | 1.48K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying VKTX stock.
For fiscal year 2025, Viking Therapeutics, Inc. (VKTX) reported total revenue of $0.0M.
Viking Therapeutics, Inc. (VKTX) reported a net loss of $359.6M for the fiscal year ending 2025.